Dr. John M. Hernandez, MD
Internal Medicine (Internal Medicine Physician)
526 N Montebello Blvd
Montebello, CA 90640
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 296
Licensed in California since 1986, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license A42641 (first issued 1986; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventist Health White Memorial Los Angeles, CA
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 296
- Services billed
- 1,469
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 482 | 123 |
| Admn sarscov2 vacc 1 dose | 92 | 92 |
| Insertion of needle into vein for collection of blood sample | 70 | 50 |
| New patient office or other outpatient visit, 15-29 minutes | 67 | 67 |
| Sarscov2 vac 50 mcg/0.5ml im | 54 | 54 |
| Established patient office or other outpatient visit, 10-19 minutes | 50 | 37 |
| Established patient office or other outpatient visit, 30-39 minutes | 48 | 36 |
| Sarscv2 vac 30mcg trs-suc im | 38 | 38 |
| Hemoglobin a1c level | 34 | 24 |
| Initial nursing facility care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 31 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 22 payments worth $572 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $118 |
|---|---|
| Mannkind Corporation | $92.16 |
| Corcept Therapeutics | $75.11 |
| Lilly USA, LLC | $73.29 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.24 |
| Novo Nordisk Inc | $49.70 |
| Exact Sciences Corporation | $33.71 |
| Kowa Pharmaceuticals America, Inc. | $28.55 |
| Food and Beverage | $529 |
|---|---|
| Education | $42.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Mannkind Corporation May 28, 2025 | Education AFREZZA · DIABETES MEDICINE · in-kind | $42.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $452,090 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Roche Molecular Systems, Inc. - Study name not reported
Roche Molecular Systems, Inc. - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
ModernaTX, Inc. · Terminated · NCT05584202 - Study name not reported
Roche Diagnostics Operations, Inc. - A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
ModernaTX, Inc. · Completed · NCT05436834
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.